Ongoing clinical trials are exploring TERT as a potential immunotherapeutic target, particularly in combination with immune checkpoint inhibitors, to enhance RT efficacy in immunosuppressive tumor microenvironments [3]. This evidence concerns the gene TERT and neoplasm.